Industry news that matters to you.  Learn more

Archives for July 2015

QIAGEN companion diagnostic wins FDA approval for use with IRESSA

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today received U.S. marketing (PMA) approval of its therascreen® EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca’s IRESSA® (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN’s therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with AstraZeneca’s drug.

DNAnexus and Intel to Deploy High-Performance Next-Gen Sequencing Analysis Software for Precision Medicine Research in the Cloud

DNAnexus, the global leader in genome informatics and data management, today announced that it has worked with Intel Corporation, the world’s largest semiconductor company, to deploy elPrep, a high-performance software tool for the preparation of genomic data for large-scale sequence analysis. The first use is by Janssen Research & Development, a division of Janssen Pharmaceutica, which is currently using elPrep in the settings of precision medicine research and clinical applications. It is the mission of Janssen R&D to discover and develop innovative medicines that ease patient’s suffering, and solve the most important unmet medical needs of our time.

The Genomic Center of Nanocenters ‘Technospark’ and ‘Dubna’, Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases

ReadSense, a genomics company at nanocenter TECHNOSPARK (Troitsk), and Strand Life Sciences, the world leader in the implementation of bioinformatics in personalized medicine, have signed a cooperation memorandum. According to the memorandum, Strand and ReadSense will jointly develop affordable tests based on next-generation sequencing (NGS) for the diagnosis of genetic pathologies such as hereditary forms of epilepsy and primary immunodeficiency disorders (PI). Moreover, Strand will engage in technology transfer in the field of genomic data analysis and bioinformatics and share their unique experience in the development of their diagnostic business in the United States and India. As part of this cooperation, ReadSense will conduct the DNA analysis of blood samples and use the integrated solutions developed by Strand to interpret the results. The focus areas of work include neurology, gastroenterology, and pulmonology.

Sanguine Brings Smart Technology and Mobile Health Force to the Clinical Trial Space

Sanguine, a leading technology company providing services to the personalized medicine and biomedical research market, recently announced that they will be expanding their services to improve clinical trial efficiency through enhanced patient recruitment, retention and trial procedures. Sanguine, which primarily operated in the pre-clinical space until now, will be fulfilling a big need in later stage clinical development through a combination of their smart technology and adaptable mobile health force.

QIAGEN expands QIAsymphony Test Menu in Partnership with Seegene

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced a collaboration in which Seegene Inc. (096530.KQ) will develop a menu of multiplex assay panels for its modular QIAsymphony RGQ MDx automation platform.